| Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran | Frank Vinluan | 04/13/20 | Boston |
| Mark Levin Named Xconomy’s 2019 Lifetime Achievement Award Winner in Boston | Angela Shah | 07/31/19 | National |
| Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases | Ben Fidler | 04/08/19 | Boston |
| Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More | Alex Lash | 01/11/19 | National |
| BIO Has Big Diversity Goals. Does It Have the Means to Reach Them? | Alex Lash | 10/11/18 | National |
| Xconomy Awards 2018 Gala Honors the Best of Boston Life Science: Slideshow | Corie Lok | 10/11/18 | Boston |
| The Winners of the 2018 Xconomy Awards Are… | Corie Lok | 09/05/18 | Boston |
| Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug | Ben Fidler | 08/10/18 | Boston |
| Down the Stretch: Akcea, Alnylam Face Reality Checks as FDA Dates Loom | Alex Lash | 07/06/18 | Boston |
| The Art of Perseverance: Meet Xconomy’s Six CEO Award Finalists | Ben Fidler | 07/02/18 | Boston |
| The 2018 Xconomy Awards Finalists Are… | Corie Lok | 06/28/18 | Boston |
| Take Two: Biotech Party with Nearly Nude Women Condemned by Industry Leaders | Corie Lok | 06/13/18 | Boston |
| Brii Biosciences Debuts with a China Pharma Strategy Backed by $260M | Frank Vinluan | 05/24/18 | Raleigh Durham |
| In Week of Hemophilia News, Alnylam Drug Cleared to Move Forward | Ben Fidler | 12/15/17 | Boston |
| Alnylam Data Puts a Nobel Discovery One Step Closer to Approved Drug | Ben Fidler | 09/20/17 | Boston |
| To Infinity and Beyond: Julian Adams on Missteps and His New Job | Ben Fidler | 04/03/17 | Boston |
| Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO | Ben Fidler | 02/23/17 | Boston |
| Biotech Leaders Sign Letter Condemning Trump’s Travel Ban | Ben Fidler | 02/07/17 | National |
| Alnylam Scraps RNAi Drug After Safety Problems, Shares Plunge | Ben Fidler | 10/05/16 | Boston |
| Making the Price Right: Ideas To Change Drug Costs Gain Momentum | Alex Lash | 04/05/16 | National |
| CRISPR Hits Wall Street as Editas Bags $94M in IPO | Ben Fidler | 02/02/16 | Boston |
| Grail’s Discount, Pfizergan & Pricing Plans: Notes from the JPM Vortex | Alex Lash | 01/15/16 | National |
| Celgene Cozies up to Nurix With $150M Drug Development Deal | Ben Fidler | 09/16/15 | San Francisco |
| East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston |
| Arrowhead’s Novartis RNAi Deal: Big Boost or ‘Stale Potato Chips’? | Jeff Bauter Engel | 03/09/15 | Wisconsin |
| Investors Line up For Westphal as Muscle Cramp Startup Upsizes IPO | Ben Fidler | 01/28/15 | Boston |
| East Coast Biotech Roundup: Alnylam, Stock Offerings, Curis, & More | Ben Fidler | 01/23/15 | Boston |
| Alnylam CEO: More Cash in Hand Is to Fuel Expansion From Within | Ben Fidler | 01/21/15 | Boston |
| 14 for ’14: Xconomy’s Top Innovation Stories of the Year | Gregory T. Huang | 12/29/14 | National |
| Xconomy Boston’s Top Stories of Q3 2014: Editor’s Picks | Gregory T. Huang | 10/01/14 | Boston |
